menu
    • menu

    Company profile for OncoSec Immunotherapies

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. Our core technology platform continues to advance through clinical trials for various cancers. Our plasmid DNA delivery platform is designed to boost th...
    OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. Our core technology platform continues to advance through clinical trials for various cancers. Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncoSec ImmunotherapiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    24 N Main Street Pennington, NJ 08534
    Telephone
    Telephone
    855-662-6732
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncosec.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncosec-medical-inc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/oncosec

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OncoSec Announces $2 Million Registered Direct Offering Under Nasdaq Rules
    OncoSec Announces $2 Million Registered Direct Offering Under Nasdaq Rules

    10 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncosec-announces-2-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-301793349.html

    PR NEWSWIRE
    10 Apr 2023
    Share Share
    OncoSec blindsided as blinded review reveals Keytruda combo flop
    OncoSec blindsided as blinded review reveals Keytruda combo flop

    04 Apr 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/oncosec-blindsided-blinded-review-reverses-early-impression-reveals-keytruda-combo-study

    Nick Paul Taylor FIERCE BIOTECH
    04 Apr 2023
    Share Share
    OncoSec sheds 45% of staff to fund IL-12 through Keytruda trial
    OncoSec sheds 45% of staff to fund IL-12 through Keytruda trial

    05 Oct 2022

    // James Waldron FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/oncosec-sheds-45-staff-fund-il-12-drug-through-keytruda-combo-trial

    James Waldron FIERCEBIOTECH
    05 Oct 2022
    Share Share
    Penny stock, Merck partner lays off 45% of staff to reach PhII readout by 2023
    Penny stock, Merck partner lays off 45% of staff to reach PhII readout by 2023

    05 Oct 2022

    // Max Gelman ENDPTS

    https://endpts.com/penny-stock-merck-partner-lays-off-45-of-staff-to-reach-two-phii-readouts-by-early-2023/

    Max Gelman ENDPTS
    05 Oct 2022
    Share Share
    OncoSec collaborates with Merck for KEYNOTE-C87 phase 3 trial
    OncoSec collaborates with Merck for KEYNOTE-C87 phase 3 trial

    08 Jul 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=139850&sid=2

    PHARMABIZ
    08 Jul 2021
    Share Share
    OncoSec collaborates with Merck for KEYNOTE-C87 phase 3 trial
    OncoSec collaborates with Merck for KEYNOTE-C87 phase 3 trial

    08 Jul 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=139850&sid=2

    PHARMABIZ
    08 Jul 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search